A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in Situ of the breast

Clinical Cancer Research

Volumn 20, Issue 14, 2014, Pages 3672-3682

  Lee, Oukseub ^a   Page, Katherine ^c   Ivancic, David ^a   Helenowski, Irene ^a   Parini, Vamsi ^a   Sullivan, Megan E ^a   Margenthaler, Julie A ^f   Chatterton Jr , Robert T ^a   Jovanovic, Borko ^a   Dunn, Barbara K ^e   Heckman Stoddard, Brandy M ^e   Foster, Kathleen ^e   Muzzio, Miguel ^d   Shklovskaya, Julia ^c   Skripkauskas, Silvia ^c   Kulesza, Piotr ^a   Green, David ^b   Hansen, Nora M ^a,c   Bethke, Kevin P ^a,c   Jeruss, Jacqueline S ^a,c   Bergan, Raymond ^b,c   Khan, Seema A ^a,c   more..

^a Department of Surgery ^*  (United States)

^b Division of Hematology/Oncology   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d IIT RESEARCH INSTITUTE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; BLOOD CLOTTING FACTOR 8; KI 67 ANTIGEN; PLACEBO; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TAMOXIFEN; TUMOR MARKER; VON WILLEBRAND FACTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; HYDROXYTAMOXIFEN;

ADIPOSE TISSUE; ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FEMALE; HOT FLUSH; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LIQUID CHROMATOGRAPHY; NIPPLE ASPIRATION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PREMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; ANALOGS AND DERIVATIVES; BLOOD; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CLINICAL TRIAL; COMPARATIVE STUDY; CUTANEOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84904399469     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3045     Document Type: Article

References (48)

1. Weaver DL, Rosenberg RD, Barlow WE, Ichikawa L, Carney PA, Kerlikowske K, et al. Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer 2006;106:732-42. (Pubitemid 43238438)
2. Ward E, Desantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014;64:83-103.
3. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000. (Pubitemid 29271743)
4. Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011;103:478-88.
5. Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 2004;100:1800-6. (Pubitemid 38529556)
6. Yen TW, Hunt KK, Mirza NQ, Thomas ES, Singletary SE, Babiera GV, et al. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer 2004;100:942-9. (Pubitemid 38222854)
7. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001;8:580-5. (Pubitemid 32735038)
8. Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, et al. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 2005;103:1996-2005. (Pubitemid 40605105)
9. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
10. Day R, Ganz PA, Costantino J, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Adjuvant Breast and Bowel Project P-1 study. J Surg Oncol 1999;17:2659-69. (Pubitemid 29415221)
11. Ackerman AB, Kessler G, Gyorfi T, Tsou HC, Gottlieb GJ. Contrary view: the breast is not an organ per se, but a distinctive region of skin and subcutaneous tissue. Am J Dermatopathol 2007;29:211-8. (Pubitemid 46573098)
12. Pujol H, Girault J, Rouanet P, Fournier S, Grenier J, Simony J, et al. Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue. Cancer Chemother Pharmacol 1995;36:493-8.
13. Rouanet P, Linares-Cruz G, Dravet F, Poujol S, Gourgou S, Simony-Lafontaine J, et al. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen. J Clin Oncol 2005;23:2980-7. (Pubitemid 46224117)
14. Lazzeroni M, Serrano D, Dunn BK, Heckman-Stoddard BM, Lee O, Khan S, et al. Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug. Breast Cancer Res 2012;14:214.
15. Mansel R, Goyal A, Nestour EL, Masini-Eteve V, O'Connell K. A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women. Breast Cancer Res Treat 2007;106:389-97. (Pubitemid 350029684)
16. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010;134:e48-72.
17. Cella D, Land SR, Chang CH, Day R, Costantino JP, Wolmark N, et al. Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Res Treat 2008;109:515-26. (Pubitemid 351692068)
18. Chatterton RT Jr, Khan SA, Heinz R, Ivancic D, Lee O. Patterns of sex steroid hormones in nipple aspirate fluid during the menstrual cycle and after menopause in relation to serum concentrations. Cancer Epidemiol Biomarkers Prev 2010;19:275-9.
19. Liu Z, Shi HY, Nawaz Z, Zhang M. Tamoxifen induces the expression of maspin through estrogen receptor-a. Cancer Lett 2004;209:55-65. (Pubitemid 38625745)
20. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004;90:423-9. (Pubitemid 38250640)
21. Wynes MW, Konopa K, Singh S, Reyna-Asuncion B, Ranger-Moore J, Sternau A, et al. Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and showgreat variability in non-small cell lung cancer. J Thorac Oncol 2012;7:982-92.
22. CDER. Guidance for the industry: bioanalytical method validation. 2001. U.S.Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine (CVM).
23. Green D, McMahon B, Foiles N, Tian L. Measurement of hemostatic factors in EDTA plasma. Am J Clin Pathol 2008;130:811-5.
24. Dowsett M, Smith I, Robertson J, Robison L, Pinhel I, Johnson L, et al. Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J Natl Cancer Inst Monogr 2011;2011:120-3.
25. Barker S, Malouitre SD, Glover HR, Puddefoot JR, Vinson GP. Comparison of effects of 4-hydroxy tamoxifen and trilostane on oestrogen-regulated gene expression in MCF-7 cells: up-regulation of oestrogen receptor beta. J Steroid Biochem Mol Biol 2006;100:141-51. (Pubitemid 44175836)
26. Umekita Y, Yoshida H. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma. Histopathology 2003;42:541-5. (Pubitemid 36688147)
27. Allen KE, Clark ER, Jordan VC. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br J Pharmacol 1980;71:83-91. (Pubitemid 11167766)
28. Borgna JL, Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem 1981;256:859-68. (Pubitemid 11103040)
29. Robertson DW, Katzenellenbogen JA, Long DJ, Rorke EA, Katzenellenbogen BS. Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem 1982;16:1-13. (Pubitemid 12158097)
30. Mauvais-Javis P, Baudot N, Castaigne D, Banzet P, Kuttenn F. Trans-4-hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast. Cancer Res 1986;46:1521-5. (Pubitemid 16048306)
31. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-8.
32. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-21. (Pubitemid 47555336)
33. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor a for degradation in breast cancer cells. Cancer Res 2009;69:1722-7.
34. Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N- desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005;55:471-8. (Pubitemid 40568978)
35. Lim YC, Li L, Desta Z, Zhao Q, Rae JM, Flockhart DA, et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 2006;318:503-12. (Pubitemid 44061223)
36. Lee O, Ivancic D, Chatterton RT, Rademaker A, Khan SA. In vitro human skin permeation of endoxifen: potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast. Breast Cancer 2011;3:61-70.
37. Lonning PE, Lien EA, Lundgren S, Kvinnsland S. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 1992;22:327-58.
38. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, et al. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 2004;10:2336-43. (Pubitemid 38445691)
39. Ellmen J, Hakulinen P, Partanen A, Hayes DF. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res Treat 2003;82:103-11. (Pubitemid 37476010)
40. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-90. (Pubitemid 36798424)
41. Cosman F, Baz-Hecht M, Cushman M, Vardy MD, Cruz JD, Nieves JW, et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb Res 2005;116:1-13.
42. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300. (Pubitemid 36126189)
43. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24. (Pubitemid 35257944)
44. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302:1429-36.
45. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ. Estrogen receptor expression in benign breast epithelium and breast cancer risk [see comments]. J Natl Cancer Inst 1998;90:37-42. (Pubitemid 28078079)
46. Ricketts D, Turnbull L, Ryall G, Bakhshi R, Rawson NSB, Gazet JC, et al. Estrogen and progesterone receptors in the normal female breast. Cancer Res 1991;51:1817-22.
47. Povoski SP, Olsen JO, Young DC, Clarke J, Burak WE, Walker MJ, et al. Prospective Randomized trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol 2006;13:1412-21. (Pubitemid 44749652)
48. Klimberg VS, Rubio IT, Henry R, Cowan C, Colvert M, Korourian S. Subareolar versus peritumoral injection for location of the sentinel lymph node. Ann Surg 1999;229:860-4.